Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 779 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma July 1, 2020 Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical... March 2, 2021 Load more HOT NEWS Tough questions for tough times in clinical research News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into...
